Leishmania ribonucleoside metabolism

*Leishmania ribonucleoside metabolism* comprises multiple essential metabolic routes enabling the parasite to salvage and utilize ribonucleosides and nucleotides necessary for its survival. Unlike many eukaryotes, *Leishmania* species are auxotrophic for purines—they cannot synthesize purine rings de novo, relying on salvage pathways to incorporate host-derived purines via specific enzymes (e.g., APRT, HGPRT, XPRT) and transporters (e.g., folate-biopterin transporters)[3][5][6]. Many components of these pathways differ structurally and functionally from host counterparts, making them attractive targets for anti-leishmanial drugs[2][6]. Drug targeting typically focuses on inhibiting key enzymes or disrupting the uptake and utilization of essential metabolites, but therapeutic development is complicated by pathway redundancy and shared homology with host proteins, posing risks of toxicity and resistance[2][6].\n\nThis entry does not map to a single, structurally-defined molecular target; rather, it encompasses a set of enzymes and transporters, principally those involved in purine and folate salvage and nucleotide biosynthesis. For structured data, each enzyme or transporter should be listed individually as a canonical target if deeper annotation is required.

Inhibition of purine salvage enzymes (e.g., HGPRT inhibition by allopurinol)\nBlockade of folate metabolic pathways and transporters (e.g., methotrexate uptake)\nDisruption of nucleotide biosynthesis and energy metabolism